$DWAVE QUANTUM INC C/WTS (TO PUR COM) (QBTS.WS.US)$
Among the quantum computing companies, Rigetti Computing reported the smallest annual net loss in 2023 at $75.1 million, compared to IonQ's $157.8 million and D-Wave's $54.3 million Adjusted EBITDA loss (a different metric) for the same year1. While all three companies are still operating at a loss, Rigetti appears to have managed its losses better than IonQ in absolute terms. However, D-Wave shows potential improvement, projecting lower losses ...
Among the quantum computing companies, Rigetti Computing reported the smallest annual net loss in 2023 at $75.1 million, compared to IonQ's $157.8 million and D-Wave's $54.3 million Adjusted EBITDA loss (a different metric) for the same year1. While all three companies are still operating at a loss, Rigetti appears to have managed its losses better than IonQ in absolute terms. However, D-Wave shows potential improvement, projecting lower losses ...
2
103673643
voted
Donald Trump’s inauguration is just away, but key crypto legislation may take a little longer to come into effect.
Other important crypto legislation, such as rules governing stablecoins and a bill to clarify the securities and commodities regulator’s roles in policing crypto, “may take some time to pass,” as a reinvigorated conservative and free market legislature “may be less willing to compromise on points than when liberal...
Other important crypto legislation, such as rules governing stablecoins and a bill to clarify the securities and commodities regulator’s roles in policing crypto, “may take some time to pass,” as a reinvigorated conservative and free market legislature “may be less willing to compromise on points than when liberal...
+3
20
3
2
$Longeveron (LGVN.US)$
longeveron.com/...
why can't break thru $3?
Alzheimer's Disease and HLHS
Alzheimer's disease therapeutics market is expected to reach USD 6.3 billion by 2034, growing at a CAGR of 6.8% during the same period.
longeveron.com/...
why can't break thru $3?
Alzheimer's Disease and HLHS
Alzheimer's disease therapeutics market is expected to reach USD 6.3 billion by 2034, growing at a CAGR of 6.8% during the same period.
2
$Longeveron (LGVN.US)$
Longeveron Reports Positive FDA Type C Meeting on BLA Pathway for Lomecel-B in HLHS
The Phase 2B trial for the CLEAR MIND study, which evaluates Lomecel-B for mild Alzheimer's disease, is anticipated to start following a meeting with the FDA before the end of 2024. This meeting aims to outline the future clinical and regulatory strategy for Lomecel-B, based on the positive results from the Phase 2A trial. Specific timelines for initiating the Phase 2B trial will depend on t...
Longeveron Reports Positive FDA Type C Meeting on BLA Pathway for Lomecel-B in HLHS
The Phase 2B trial for the CLEAR MIND study, which evaluates Lomecel-B for mild Alzheimer's disease, is anticipated to start following a meeting with the FDA before the end of 2024. This meeting aims to outline the future clinical and regulatory strategy for Lomecel-B, based on the positive results from the Phase 2A trial. Specific timelines for initiating the Phase 2B trial will depend on t...
$Longeveron (LGVN.US)$
How might Lomecel-B's approval influence other Alzheimer's treatments
If Lomecel-B receives FDA approval, it could significantly influence other Alzheimer's treatments in several ways:
1. **Market Dynamics**: Approval may shift market focus towards regenerative therapies, encouraging more investment and research in stem cell and regenerative medicine approaches for Alzheimer's, potentially leading to a broader range of treatment options.
2. **Competitive Pressure**: Esta...
How might Lomecel-B's approval influence other Alzheimer's treatments
If Lomecel-B receives FDA approval, it could significantly influence other Alzheimer's treatments in several ways:
1. **Market Dynamics**: Approval may shift market focus towards regenerative therapies, encouraging more investment and research in stem cell and regenerative medicine approaches for Alzheimer's, potentially leading to a broader range of treatment options.
2. **Competitive Pressure**: Esta...
1
$Longeveron (LGVN.US)$
if Fda approved what will happen
If the FDA approves Lomecel-B for Alzheimer's disease, several significant outcomes can be expected:
1. **Market Launch**: Lomecel-B would become available for prescription, providing a new treatment option for patients with mild Alzheimer's disease, potentially impacting the estimated $15.9 billion Alzheimer's treatment market by 2030[1].
2. **Increased Stock Value**: Approval could lead to a substantial increase in Longeveron's stock pr...
if Fda approved what will happen
If the FDA approves Lomecel-B for Alzheimer's disease, several significant outcomes can be expected:
1. **Market Launch**: Lomecel-B would become available for prescription, providing a new treatment option for patients with mild Alzheimer's disease, potentially impacting the estimated $15.9 billion Alzheimer's treatment market by 2030[1].
2. **Increased Stock Value**: Approval could lead to a substantial increase in Longeveron's stock pr...
12
$Longeveron (LGVN.US)$ someone is manipulative on the price
2
1
$Longeveron (LGVN.US)$
fast track means in a couple of months if they passed the phase 3 trial in terms of efficacy and safety they could be granted approval..
CEO/CSO has been buying up shares since April 2024 in a sizable amount.
U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease
Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS ha...
fast track means in a couple of months if they passed the phase 3 trial in terms of efficacy and safety they could be granted approval..
CEO/CSO has been buying up shares since April 2024 in a sizable amount.
U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease
Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS ha...
1
$Longeveron (LGVN.US)$
biggest player in the segment and it's value
biggest player in the segment and it's value
1
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)